NCT00871494 - Study Of Azithromycin Intravenous Formulation Against Pelvic Inflammatory Disease (PID) In Japan | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions

Pelvic Inflammatory Disease

Interventions

DRUG

Azithromycin

The patients will receive 500 mg intravenous azithromycin QD for 1 to 2 days. The period of administration of intravenous dosing is judged by investigators according to patient status. Following intravenous administration, the patients will be received the 250 mg oral azithromycin (tablet formulation) QD to complete a total of 7 days therapy.

Trial Locations (31)

Unknown

Pfizer Investigational Site, Aichi-gun

Pfizer Investigational Site, Ichinomiya

Pfizer Investigational Site, Nagoya-city Naka-ku

Pfizer Investigational Site, Tanba-gun Fusou-chou

Pfizer Investigational Site, Hirosaki

Pfizer Investigational Site, Niihama

Pfizer Investigational Site, Kasuga

Pfizer Investigational Site, Kitakyushu

Pfizer Investigational Site, Kitakyushu-shi, Yahatanishi-ku

Pfizer Investigational Site, Chuou-ku

Pfizer Investigational Site, Fukushima

Pfizer Investigational Site, Takasaki

Pfizer Investigational Site, Takasaki-shi

Pfizer Investigational Site, Hakodate-shi Goryoukaku-cho

Pfizer Investigational Site, Hakodate-shi Hon-cho

Pfizer Investigational Site, Sapporo

Pfizer Investigational Site, Chuo-ku

Pfizer Investigational Site, Kobe

Pfizer Investigational Site, Kounoike Shinmachi

Pfizer Investigational Site, Kagoshima

Pfizer Investigational Site, Kamigyou-ku

Pfizer Investigational Site, Nagano

Pfizer Investigational Site, Suzaka-shi

Pfizer Investigational Site, Okayama

Pfizer Investigational Site, Koshigaya

Pfizer Investigational Site, Aoba-ku

Pfizer Investigational Site, Meguro-ku

Pfizer Investigational Site, Minato-ku

Pfizer Investigational Site, Nakaku

Pfizer Investigational Site, Fukushima